| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-11 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-09 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-08 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.25 | 7e-08 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-07 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-07 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-07 |